🔥Telegram İfşa

LANDMARK will be an invaluable resource for those studying for FRCS(urol), preparing for teaching sessions/grand rounds and keeping up to date with/reviewing seminal papers in urology

🌐 Introducing #LANDMARK by BURST. 🔗 This FREE innovative platform is designed to streamline your access to key urology research papers and summaries. 🚀 Check it out at: landmark.bursturology.com #UroSoMe

📣Excited to announce from Perth, WA, initial participant dosed in the first in-human study #GDISCO; Gemcitabine-Docetaxel Intravesical Synchronous CO-administration for BCG unresponsive HR-NMIBC (ANZUP2403). ASCO #GU25 ANZUP UWA #SMHS

Excited to share our latest publication from FSH on the role of nuclear medicine in urothelial cancer. This review explores emerging tracers, theranostics, and the future of molecular imaging in optimising diagnosis & treatment #UroOncology ANZUP pubmed.ncbi.nlm.nih.gov/39858014/

🎉 Celebrating 10 years of BURST! 🚀 From high-impact multi-centre research to our incredible community, we’ve come a long way. Thank you for being part of the journey! 💙 ❗️Committee recruitment open: is.gd/BURST25Rec #BURST10 #UroSoMe

✨ "Through BURST, I have strengthened my teaching abilities and promoted evidence-based practices in urology, all while making a meaningful difference." - Mr Kevin Keane, Core Committee Join us as we celebrate #BURST10 🎉 🫵 Apply here: is.gd/BURST25Rec #UroSoMe

Congrats to our @ANZUPTrials #GDISCO (ANZUP 2403) TiP poster presented ASCO #GU25 by Kevin Keane! Well done to all involved in this important #BladderCancer study #ProfDickonHayne Cancer Australia Ian Davis (Bluesky @profiand)

It’s a wrap ASCO #GU25! Our final @ANZUPTrials poster #SUBDUE3 #BladderCancer study presented by Kevin Keane. Study led by Prof Dickon Hayne and supported by #SouthMetropolitanHealthService UWA Cancer Australia Ian Davis (Bluesky @profiand)

An insightful evening at the RUM@UWA event with Prof Chris Sweeney sharing expertise on treatment modalities in high-risk prostate cancer. Updates from ASCO GU 2025 and future directions in mHSPC and localised disease. UWA Christopher Sweeney, MBBS

Ashish M. Kamat, MD, MBBS Merck IBCG UroToday.com Shilpa Gupta Roger Li Patrick Hensley, MD World Bladder Cancer Patient Coalition Bladder Cancer Advocacy Network Prof Param Mariappan FRCS(Urol), PhD Benjamin J. Davies MD Sia Daneshmand, M.D. Great to hear this. There could be another solution too. Come to the #ASCO25 Kidney and Bladder oral session on Sunday morning shortly before 11am to hear Prof Dickon Hayne present the BCG-Mitomycin ANZUP ANZUP 1301 #NMIBC outcomes (abstract LBA4504). #BladderCancer #blcsm

After listening to BONO for 5 minutes on Joe Rogan I now realize he’s one of the dumbest human beings on planet earth. A worm has a higher IQ.

#BCGMM presented by Dickon Hayne at #ASCO25. Simple question, hard trial, needed a cooperative group like ANZUP NHMRC CTC. Discussant Dr. John Sfakianos v enthusiastic, one of the most impactful #NMIBC trials he has seen, will change his practice. #BladderCancer #blcsm

Well done! The @ANZUPTrials #BCGMM trial has been presented @ASCO25 showing BCG plus mitomycin a safe & effective alternative to BCG alone & the added benefit of requiring 40% fewer BCG doses. Congrats to Prof Dickon Hayne & team Ian Davis NHMRC CTC @MSD_Aus #OmegaPharm

Mitomycin + BCG as adjuvant intravesical therapy for high-risk #NMIBC: a randomized phase 3 trial (ANZUP 1301). Presentation by Dickon Hayne, MD, FRCS. #ASCO25 written coverage by Zach Klaassen > bit.ly/3Zaimmv ASCO

Great to see Prof Dickon Hayne talking to Norman Swan about the @ANZUPTrials #BCGMM study in the latest ABC Australia Radio National Health Report Ian Davis (Bluesky @profiand) Cancer Australia abc.net.au/listen/program…

Dickon Hayne presenting the results from BCG+MMC trial in the BCG-naive setting 👉 Possible signal in higher staged patients 👉 High compliance 👉 Saves BCG in the era of shortage 🤔 Difference between monthly maintenance vs swog 🤔 Effect additive vs synergistic ANZUP

Perioperative EVP shows ⬆️ EFS,OS & pCR vs cystectomy alone in high risk cisplatin ineligible MIBC (KN901). Highly active systemic vs surgery will rescue many patients with aggressive micrometastatic disease. CRs for EVP=30% in M1 but should be ⬆️ in MIBC biospace.com/press-releases…

Hanging up his clogs having worked in The Mater for as long as I have been alive. I’m so proud of all he has achieved and the legacy he leaves behind. Delighted to have had the chance to see him in action and will always cherish the memories of getting to scrub in together

A Mater legend and a great mentor to countless Irish trainees